It is estimated that over 7% of the population in Southeast Asia suffer from Chronic Respiratory Disease with asthma and COPD amongst the most common chronic respiratory diseases

Singapore-based startup Aevice Health has raised undisclosed funding from Indonesia-based East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia. The funding will be used to expand access to Aevice Health’s flagship solution, the AeviceMD Monitoring System, to millions of patients with chronic respiratory diseases in Southeast Asia.

The company develops innovative solutions like the AeviceMD Monitoring System which provides a comprehensive patient management platform targeted towards chronic respiratory disease management.

In recent times, numerous countries across Southeast Asia have embraced a proactive stance in combating chronic diseases. Notably, Indonesia has spearheaded pilot programs that equip early adopters with wearables to monitor their health and achieve better outcomes.

This funding announcement follows closely on the heels of two significant milestones for AeviceMD. Just last week, the US Food and Drug Administration (FDA) granted the solution clearance as a Class II medical device. Back in March, the Singapore Health Sciences Authority (HSA) granted the AeviceMD first-in-market approval. These approvals enable the company to market and provide its remote monitoring platform in these key markets. Aevice Health will work closely with East Ventures and its partners to bring its novel solution into Southeast Asia.